title: Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial.
abstract: BACKGROUND
  Prednisone treatment is used to prolong ambulation in patients with Duchenne muscular dystrophy (DMD). However, since severe adverse effects often accompany prednisone treatment, it is debatable whether the benefits of prednisone treatment outweigh its adverse effects.
  
  
  OBJECTIVE
  To study the effects of prednisone on muscle function and to determine the extent of steroid-related adverse effects and their influence on the quality of life of ambulant patients with DMD.
  
  
  METHODS
  A randomized, placebo-controlled, crossover trial with 6 months of treatment: prednisone or placebo (0.75 mg/kg daily) during the first 10 days of each month. After a washout period of 2 months, patients received the other regimen for an additional 6 months.
  
  
  METHODS
  University hospital and rehabilitation center in the Netherlands.
  
  
  METHODS
  Seventeen ambulant patients with DMD aged 5 to 8 years.
  
  
  METHODS
  Change in muscle function assessed by timed functional testing: running 9 m, climbing 4 standard-sized stairs, and rising from the floor to a standing position.
  
  
  RESULTS
  The increase in time needed to run 9 m (P = .005) and to climb 4 standard-sized stairs (P = .02) was significantly lower during the prednisone period.
  
  
  CONCLUSIONS
  Prednisone slowed deterioration of muscle function and muscle force in ambulant patients with DMD. Although adverse effects were present, patient quality of life was not affected. Therefore, short-term prednisone treatment can be recommended to preserve motor functions in ambulant patients with DMD.
authors.affiliation: Department of Neurology, University Hospital Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands. e.a.c.beenakker@neuro.azg.nl
authors.forename: Ernesto A C
authors.initials: EA
authors.lastname: Beenakker
authors.forename: Johanna M
authors.initials: JM
authors.lastname: Fock
authors.forename: Marja J
authors.initials: MJ
authors.lastname: Van Tol
authors.forename: Natalia M
authors.initials: NM
authors.lastname: Maurits
authors.forename: Hendrik M
authors.initials: HM
authors.lastname: Koopman
authors.forename: Oebele F
authors.initials: OF
authors.lastname: Brouwer
authors.forename: Johannes H
authors.initials: JH
authors.lastname: Van der Hoeven
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects; D020388:Muscular Dystrophy, Duchenne / Q000188:drug therapy*; D009460:Neurologic Examination; D011241:Prednisone / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone